RHINO-ORBITO-CEREBRAL MUCORMYCOSIS (BLACK FUNGUS) IN COVID 19 PATIENTS

Authors: Keshav Gupta (1) Mohit Srivastava* (2), Veenita Singh (3)

Authors Affiliations: (1) Senior Resident, (2) Professor & Head, Department of ENT, GSMCH Hapur Uttar Pradesh, (3) Professor Oral & Maxillo-Facial Surgeon; Dy Patil University Mumbai Maharashtra.

ABSTRACT

BACKGROUND

Mucormycosis (Black fungus) is a designated as a rare, rapidly progressive fatal disease of immunocompromised caused by saprophytic fungus of family mucorales. Early diagnosis with prompt medical and surgical treatment is the only tool available. Rhino-orbito-cerebral is the most common subtype. In India we saw a sudden rise in mucormycosis cases during second wave of COVID 19. This necessitated a systematic review of epidemic of mucormycosis in COVID 19.

METHODS

A Retrospective multi-centric study was conducted at various Government and Private Hospitals of Western UP comprising of 51 cases of Rhino-orbito-cerebral mucormycosis with present or recent COVID19 positive status presenting to us during 14th April 2021- 31st May 2021.

RESULT

Either Type2 Diabetes Mellitus or history of recent use of steroids in high doses was present in all the patients. Contribution of virulence of the Delta strain B.1.617.2 is significant. FESS with sino-nasal debridement contributes significantly towards mortality reduction and cost of total treatment by significantly reducing days of Liposomal Amphotericin B therapy.

CONCLUSION

Early diagnosis with prompt medical and surgical management along with blood sugar control and avoiding use of high dose of steroids remain to key to mortality and morbidity reduction.

Keywords: Black fungus, mucor, mucormycosis, rhino-orbito-cerebral, causes, treatment, covid 19,

India, sugar, steroids, steam, oxygen, surgery.

Funding: None

Conflicts of interest: None

INTRODUCTION

Mucormycosis are a group of invasive infections caused by filamentous fungi of the Mucoraceae family¹. It is the third invasive mycosis in order of importance after candidiasis and aspergillosis². The incidence of mucormycosis is approximately 1.7 cases per 1000000 inhabitants per year, and the main risk-factors for the development of mucormycosis are ketoacidosis (diabetic or other), iatrogenic immunosuppression, use of corticosteroids or deferoxamine, disruption of mucocutaneous barriers by catheters and other devices, and exposure to bandages contaminated by these fungi².

Rhino-orbito-cerebral is the most common clinical subtype of disease. Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality³. This form presents with sinusitis, facial and eye pain, proptosis, progressing to signs of orbital structure involvement^{4,5,6,7}. Necrotic tissue can be seen on nasal turbinates, septum and palate. This may look like a black eschar^{7,8}. Intracranial involvement develops as the fungus progresses through either the ophthalmic artery, the superior fissure, or the cribriform plate^{4,7}.

Diagnosis of mucormycosis rests upon the presence of predisposing conditions, signs and symptoms of disease, observation of fungal elements of specific morphology in histological sections, and direct smears of material, and, to a lesser extent, culture results^{6,7}. There are no reliable serological tests for diagnosis at present⁸.

The incidence of mucormycosis has risen more rapidly during the second wave compared with the first wave of COVID 19 in India, with atleast 28,252 mucormycosis cases on 7th June 2021. 86% of them are known to have history of COVID 19 and 62.3% of them are known to be diabetic⁹.

AIM

To study various risk factors, clinical features, diagnosis, treatment and outcome of mucormycosis patients during second wave of COVID 19 in Western UP in India.

STUDY DESIGN

This is a Multi-centric Retrospective study. The retrospective data was collected from various Government and Private Institutes in Western UP.

SAMPLE SIZE

No of cases- 51

Study period- 14th April 2021- 31st May 2021

INCLUSION CRITERIA

All the following criteria was satisfied

Patient presented during 14th April 2021 midnight- 31st May 2021 midnight.

COVID 19 RT PCR positive at any time during the study period or within 28 days before beginning of study period.

Biopsy proven mucormycosis and/or patient had features clinically consistent with diagnosis of mucormycosis, that is, two or more of following on presentation:

Black eschar within oral cavity and/or blackish eschar within nasal cavity and/or blackish eschar over face

Severe facial pain and facial swelling of onset within last 28 days

Eye swelling and/or Ptosis and/or proptosis

Computerized tomography or magnetic resonance and imaging suggestive of invasive fungal rhinosinusitis

EXCLUSION CRITERIA

Oral and sino-nasal malignancies, other conditions associated with oro-mucosal ulcerations, absence of present or recent COVID 19 status.

MATERIAL AND METHODS

After all inclusion and exclusion criteria were satisfied, records were checked for presence and absence of various predisposing factors, treatment offered, histopathology reports, surgeries performed and outcome.

All the data was gathered and tabulated in Microsoft Excel 2008 spreadsheet. SPSS 24 was used for statistical calculations. Results were systemized and summarized.

OBSERVATIONS

Sex	No of cases
Male	28
Female	23
Total	51

Table 1.1: Sex distribution of cases

Male to female ratio is 1.21:1 which is not a significant difference ($p < 0.05$)

Age distribution	No of cases
Less than 31	2
31-45	22
46-60	18
More than 60	9
Total	51

Table 1.2: Age distribution of cases

Out of 51 patients, 22 belonged to age group 31-45 which is a significant value ($p > 0.05$)

COVID Status	No of cases
Active COVID	25
Post COVID	26
Total	51

Table 1.3: COVID status of patients

Out of 51 patients, 25 had active COVID infection which is not a significant difference ($p < 0.05$)

Risk Factor	No. of cases	Association
Diabetic	43	Strong
Recent history of Steroids	49	Strong
Either Diabetes or steroids	51	Definitive
Oxygen support	16	Weak
History of Tocilizumab	zero	Can not comment
Steam inhalation more than one hour a day	1	Absent

Table 1.4: Various Risk Factors for mucormycosis with Delta stain of COVID 19 noted in our study
All the patients of mucormycosis with COVID19 were either diabetics or had taken steroids or both were present. So, there is a definitive association of mucormycosis with these two risk factors.

Independently, there is a strong association between mucormycosis in COVID19 patients with steroids and diabetes.

However, strong association of mucormycosis in COVID19 patients with oxygen therapy is found to be lacking.

There is no association between steam therapy and mucormycosis in COVID19 patients.

Since, no patient with history of Tocilizumab administration is included in our study, Effect of Tocilizumab administration on mucormycosis cannot be commented from our study.

Clinical Feature	No. of cases	Frequency
Eye swelling	34	66.67
Diminished vision	29	56.86
Ptosis	28	54.90
Black eschar	25	49.02
Facial swelling	23	45.10
Proptosis	18	35.29
Facial pain	16	31.37
Loss of vision	11	21.57
Nasal discharge	8	15.69
Nasal bleed	4	7.84
Altered sensorium	1	1.96

Table 1.5: Clinical features in 51 patients of mucormycosis with COVID 19

Eye swelling is seen to be the most consistent clinical feature in mucormycosis with COVID 19 present in two-thirds of patients followed by diminished vision (57%) and ptosis (55%). Overall, ocular symptoms are more common when patients are co-infected with COVID19 when compared to mucormycosis alone.

Image 1.1 : Clinical features of mucormycosis. Clockwise: Facial swelling, oral cavity eschar, eye

swelling, facial eschar, congestion, diminished vision and ptosis of eyes.

Image 1.2: Computerised tomography.
a. Rt maxillary sinus non-homogenous opacification **b.** Rt orbital involvement with proptosis

Figure 1.2 : Computerized tomography scan showing a. Non homogenous opacification of Rt Maxillary sinus b. Rt orbital involvement with proptosis

Table 1.6: Outcome in 51 patients of mucormycosis with COVID19

Outcome	No. of patients	Frequency
Recovered during study period	18	35.29
Survived but did not recover during study period	23	45.10
Facial disfigurement	4	7.84
Permanent loss of vision from one eye	3	5.88
Permanent loss of vision from both eyes	1	1.96
Expired during study period	10	19.61

80 percent of patients survived the study period and almost half of them recovered completely

during study period itself. Out of 51 patients, 4 suffered from facial disfigurement because of the disease, 4 had permanent loss of vision from one or both eyes.

Table 1.7: Treatment offered in terms of Liposomal Amphotericin B and Debridement surgery to various patients

Treatment given	No of patients	Frequency
Liposomal Amphotericin B for 1-7 days	35	68.63
Liposomal Amphotericin B for 8-14 days	11	21.57
Liposomal Amphotericin B for more than 14 days	1	1.96
Debridement surgery	34	66.67

Two-thirds of patient underwent debridement surgery. In almost same number of patients, Liposomal Amphotericin B was required for 1 week or less. All other patients required longer treatment with Amphotericin B.

Image 1.3: A. Black Eschar in Nasal Cavity. B. Debrided Remnant of Middle Turbinate. C. Post Debridement Image.

Table 1.8: Number of patients who took surgery charted with number of patients who survived the study period

Surgery and survival	No of patients who took surgery	No of patients who did not take surgery	Total patients
No of patients survived during study period	32	9	41
No of patients expired during study period	2	8	10
Total patients	34	17	51

Almost one-third of patients undertook debridement surgery and majority of them survived the study period. 9 out of 51 patients could not be operated either because of early mortality because of disease or because of no consent for surgery from patient. Only one of them could survive through the study period. This difference in survival ratio amongst operated and non-operated patients is significant ($p > 0.05$)

Duration of Amphotericin B therapy	1-45 days
With Surgery	1-7 days
Without surgery	1-45 days

Table 1.9: Effect of surgery on duration of Amphotericin B therapy and hence cost of treatment

Also surgery led to reduction in duration of Amphotericin B therapy from 1-45 days to 1-7 days.

Duration from presentation	No of patients who expired
Within 24 hours	4
24-48 hours	2
48-72 hours	1
More than 120 hours	3
Total	10

Table 1.10: Figures of mortality from the time of presentation

Maximum mortality was seen within 24 hours of presentation which reduced subsequently on second and third day.

RESULT

The disease is equally seen in both sexes. The disease is exclusively seen in either diabetics or those who have recently taken steroids. Immuno-compromised patients with Delta strain of COVID 19 Pango lineage B.1.617.2 have more risk of developing mucormycosis than their non COVID counterparts. Oxygen inhalation also contributes to the risk. There is no positive or negative effect of steam inhalation.

There is an increase in no of cases of mucormycosis because of delta strain of COVID 19. There is a shift of peak towards the younger age groups. There is increased frequency of eye involvement. Mortality is maximum within first 72 hours of presentation. However, mortality ratio is less when co-infected with delta strain of COVID 19.

Surgery offers significant benefit by decreasing mortality, decreasing duration of Liposomal Amphotericin B treatment and hence reducing cost of treatment.

CONCLUSION

Delta strain of COVID 19 has significantly increased the incidence of mucormycosis due to its immunosuppressive effect. Excessive use of steroids has also contributed to the same. Since, patients of younger age group are affected more with this strain, the peak of mucormycosis has also shifted in the same direction. In a young patient with unatherosclerosed and more patent vessels, there is early involvement of ethmoid and opthalmic vessels and hence early necrosis of turbinates is seen alongwith prominent eye symptoms. The massive coverage of black fungus by media has made people extra conscious about the mucormycosis, which has also contributed to early presentation and early diagnosis of the disease¹⁰. Early diagnosis coupled with early surgery in younger patient may have contributed to lower mortality when recorded over a short time span.

REFERENCES

1. Mallis A, Mastronikolis SN, Naxakis SS, Papadas AT. Rhinocerebral mucormycosis: an update. *European Review for Medical and Pharmacological Sciences*. 2010; 14: 987-992.
2. Bouza E, Munoz P, Guinea J. Mucormycosis: an emerging disease? *Clinical Microbiology and infection* 2006;12(7):7-23.
3. Global guideline for the diagnosis and management of mucormycosis. Available at: [https://doi.org/10.1016/S1473-3099\(19\)30312-3](https://doi.org/10.1016/S1473-3099(19)30312-3). Accessed on May 27, 2021.
4. Strickland GT. *Hunter's Tropical Medicine*. Philadelphia, PA: WB Saunders. 1984:468-469.
5. Koneman E, Allen S. *Diagnostic Microbiology*. Philadelphia, PA: JB Lippincott. 1992:812-814.
6. Mucormycosis (Zygomycosis). Available at: <http://www.emedicine.medscape.com/oph/topic225.htm>. Updated Sep10, 2018. Accessed May 27, 2021.
7. Branscomb R. An overview of mucormycosis. *CE Update microbiology and virology*. 2002;33(6):1-3.
8. Rippon J. *Medical mycology*. Philadelphia, PA: WB Saunders. 1982:615-637.
9. Black Fungus: These 2 states account for nearly 42% of India's 28252 mucormycosis cases. June 7, 2021. Available at: <https://www.livemint.com/news/india/black-fungus/amp-11623069135171.htm>.
10. India's Black Fungus Epidemic Spread Through Hospital Air Conditioning, New Research Suggests. Available at: <https://scroll.in/article/1010105/indias-black-fungus-epidemic-spread-through-hospital-air-conditioning-new-research-suggests>.htm.

*Corresponding Author –

Dr. Mohit Srivastava,
Professor & Head ENT, GSMCH, Hapur Uttar Pradesh.
Mob- 9999556665 / dr.mohit141180@gmail.com